Press Release

Nanomedicine Therapeutic Market to Elevate with a Boost in Nanotherapies for Cancer Treatment

The Global Nanomedicine Therapeutic market is projected to grow at a CAGR of around 12.5% during the forecast period of 2023-28, cites MarkNtel Advisors in the recent research report. The major application has been utilized across the cancer treatment segment, as it has been proven to be highly effective for cancer. The drugs used for treating cancer are made to have an impact on the cell cycle process, which can be managed to prevent the division of tumor cells. The majority of cancer medications have been proven to have several side effects, including harm to non-tumorigenic cell division.

On the other hand, these medications are found to successfully carry the drug to the tumoral tissues, hence decreasing other negative effects that have been brought on by conventional medications. Therefore, with cancer as one of the leading causes of death from the disease worldwide, and nanomedicines being considered the most effective of all cancer therapeutics, their adoption has amplified considerably. Additionally, a large number of neurological & cardiovascular medications have been developed using the new physicochemical features of nanoparticles. It was mainly due to their smaller size, which enhanced their membrane permeability & improved the drug's intra- & intercellular interactions.

Nanomaterials have mostly been employed in drug research for coating purposes, which have been found to improve medication delivery inside the human body. Furthermore, liposome, which has been heavily commercialized as a Nanoscale Drug Delivery System (NDDS), was the most widely used form during 2018-2022. Also, considering the highly effective nature of liposomal nanoparticles as drug carriers, several companies, like Insmed Netherlands B.V., Glaxo Smith Kline, etc., have launched their liposome-based therapeutic drug candidates in the market during 2021-2022.

Therefore, the presence of highly effective nanomedicines against emerging diseases, along with their rising awareness among the end-users, would help in the market growth in the forecast period as well, further states the research report, “Global Nanomedicine Therapeutic Market Analysis, 2023.” 

Oncology Segment Dominated the Global Market

Based on Indication, the market is segmented into Oncology, Infectious Disease, Cardiology, Neurological Disease, and Others (Orthopaedics, Urology, etc.). Among them, Oncology has dominated the Global Nanomedicine Therapeutic market during the historical years. The fundamental reason is that nanotechnology has numerous applications in areas like cancer treatment & imaging. The majority of the drug agents generated for therapy were discovered to deliver a significant number of side effects, which led to a breakthrough in targeted therapeutics for cancer treatment with nanomedicine. Due to the fact that nanomedicines are solely intended to cure specific cancers, there are fewer adverse effects associated with cancer nanotherapies.

Additionally, as the use of nanoparticles to treat cancer becomes more widely known, there is a huge accumulation in demand for these substances. Moreover, companies like ImmunoVaccine Technologies, Inc., MedImmune LLC, and others have been heavily funding the research & development of innovative nanomedicine-based cancer medicines. These initiatives by the companies are intended to meet the anticipated demand for these medicines in oncology, primarily driven by increased awareness. Thus, the segment is therefore expected to experience upgraded growth in the predicted years.

North America to Account for Prominent Market Share

North America captured a sizeable percentage of the worldwide market, and it is presumed to have the same effect during the projection period. The rise in the number of fatal diseases like cardiovascular & cancer diseases is the prominent reason for the regional impact. Additionally, the North America Nanomedicine Therapeutic market has been supported by the presence of a world-class R&D infrastructure & an upsurge in government spending on the healthcare system. Furthermore, significant key players have been active in developing novel treatments for emerging diseases across the region, including Pacira BioSciences, Moderna, etc. Also, the presence of key players & their consistent effort to develop novel & effective therapies would help in the growth of the market during the forecasted years.

Competitive Landscape

With strategic initiatives, such as mergers, collaborations, and acquisitions, the leading market players, including Arrowhead Pharmaceuticals, Inc., Nanospectra Biosciences, Cristal Therapeutics, MagArray, Inc., BlueWillow Biologics, MagForce NT GmbH, Johnson & Johnson, Acrotech Biopharma LLC, Ipsen Pharma, RECORDATI S.p.A., Bristol-Myers Squibb Company, ratiopharm GmbH, Alnylam Pharmaceuticals, and GlaxoSmithKline plc are looking forward to strengthening their market position.

Key Questions Answered in the Research Report

1. What are the industry’s overall statistics or estimates (Overview, Size- By Value, Forecast Numbers, Segmentation, Shares)?
2. What are the trends influencing the current scenario of the market?
3. What key factors would propel and impede the industry across the globe?
4. How has the industry been evolving in terms of geography & product adoption?
5. How has the competition been shaping across various regions?
6. How has the buying behavior, customer inclination, and expectations from product manufacturers been evolving during 2018-28?
7. Who are the key competitors, and what strategic partnerships or ventures are they coming up with to stay afloat during the projected time frame?